Cargando…
Dissociation between 2-[(18)F]fluoro-2-deoxy-D-glucose positron emission computed tomography, ultrasound and clinical assessments in patients with non-severe rheumatoid arthritis, including remission
BACKGROUND: Inflammation of patients joints with severe disease activity of rheumatoid arthritis (RA) has already been visualized and quantified by 2-[(18)F]fluoro-2-deoxy-D-glucose positron emission computed tomography ([(18)F] FDG PET/CT), but little is known about the metabolic status and its rel...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8336401/ https://www.ncbi.nlm.nih.gov/pubmed/34344479 http://dx.doi.org/10.1186/s41927-021-00196-1 |
_version_ | 1783733312629506048 |
---|---|
author | Rinkin, Charline Fosse, Pacôme Malaise, Olivier Chapelier, Nathalie Horrion, Jil Seidel, Laurence Albert, Adelin Hustinx, Roland Malaise, Michel G. |
author_facet | Rinkin, Charline Fosse, Pacôme Malaise, Olivier Chapelier, Nathalie Horrion, Jil Seidel, Laurence Albert, Adelin Hustinx, Roland Malaise, Michel G. |
author_sort | Rinkin, Charline |
collection | PubMed |
description | BACKGROUND: Inflammation of patients joints with severe disease activity of rheumatoid arthritis (RA) has already been visualized and quantified by 2-[(18)F]fluoro-2-deoxy-D-glucose positron emission computed tomography ([(18)F] FDG PET/CT), but little is known about the metabolic status and its relationship with clinical and ultrasonography (US) metrology in patients with low/moderate activity or in remission. METHODS: Clinical assessments [based on 28-joint disease activity score (DAS(28)-CRP) and Clinical Disease Activity Index (CDAI)], [(18)F] FDG PET/CT, US and X-ray were performed on 63 RA patients classified into remission or low/moderate or severe disease activity groups. PET/CT was visually and then semi-quantitatively analysed by determining the standardized uptake value (SUV) of positive joints. RESULTS: Of the 1764 joints, 21.1% were tender only, 13.7% swollen only, 27.6% tender or swollen, 7.3% tender and swollen, 20.5% PET/CT-positive and 8.6% US-positive. PET and US measurements were correlated, albeit with poor concordance. The positive predictive value of PET/CT for clinical evaluation (tender and/or swollen) was low, whereas its negative predictive value was high. Highly significant differences were found with the number of PET/CT-positive joints and with cumulative SUV between “severe” and “non-severe” patients (including those in remission and those with low/moderate activity) and not between those classified as “remission” and “non-remission” or “remission” and “low/moderate activity”. Moreover, the correlation between PET/CT measurements and clinical activity was positive only in the CDAI severe disease group. In patients in remission or with low/moderate activity, only 20–30% of joints were PET/CT-negative. In remission, PET/CT and US were positive in different joints, and PET/CT-positive but US-negative joints mainly exhibited RA (38.1%) or normal (49.2%) and not osteoarthritic (12.7%) X-ray patterns. CONCLUSIONS: [(18)F] FDG PET/CT was effective at distinguishing patients with severely active disease from other patients. In non-severe RA patients, including those in remission, PET/CT results are discordant from US and clinical observations. A longitudinal analysis is needed to explore the clinical relevance of such infra-clinical disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41927-021-00196-1. |
format | Online Article Text |
id | pubmed-8336401 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-83364012021-08-04 Dissociation between 2-[(18)F]fluoro-2-deoxy-D-glucose positron emission computed tomography, ultrasound and clinical assessments in patients with non-severe rheumatoid arthritis, including remission Rinkin, Charline Fosse, Pacôme Malaise, Olivier Chapelier, Nathalie Horrion, Jil Seidel, Laurence Albert, Adelin Hustinx, Roland Malaise, Michel G. BMC Rheumatol Research Article BACKGROUND: Inflammation of patients joints with severe disease activity of rheumatoid arthritis (RA) has already been visualized and quantified by 2-[(18)F]fluoro-2-deoxy-D-glucose positron emission computed tomography ([(18)F] FDG PET/CT), but little is known about the metabolic status and its relationship with clinical and ultrasonography (US) metrology in patients with low/moderate activity or in remission. METHODS: Clinical assessments [based on 28-joint disease activity score (DAS(28)-CRP) and Clinical Disease Activity Index (CDAI)], [(18)F] FDG PET/CT, US and X-ray were performed on 63 RA patients classified into remission or low/moderate or severe disease activity groups. PET/CT was visually and then semi-quantitatively analysed by determining the standardized uptake value (SUV) of positive joints. RESULTS: Of the 1764 joints, 21.1% were tender only, 13.7% swollen only, 27.6% tender or swollen, 7.3% tender and swollen, 20.5% PET/CT-positive and 8.6% US-positive. PET and US measurements were correlated, albeit with poor concordance. The positive predictive value of PET/CT for clinical evaluation (tender and/or swollen) was low, whereas its negative predictive value was high. Highly significant differences were found with the number of PET/CT-positive joints and with cumulative SUV between “severe” and “non-severe” patients (including those in remission and those with low/moderate activity) and not between those classified as “remission” and “non-remission” or “remission” and “low/moderate activity”. Moreover, the correlation between PET/CT measurements and clinical activity was positive only in the CDAI severe disease group. In patients in remission or with low/moderate activity, only 20–30% of joints were PET/CT-negative. In remission, PET/CT and US were positive in different joints, and PET/CT-positive but US-negative joints mainly exhibited RA (38.1%) or normal (49.2%) and not osteoarthritic (12.7%) X-ray patterns. CONCLUSIONS: [(18)F] FDG PET/CT was effective at distinguishing patients with severely active disease from other patients. In non-severe RA patients, including those in remission, PET/CT results are discordant from US and clinical observations. A longitudinal analysis is needed to explore the clinical relevance of such infra-clinical disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41927-021-00196-1. BioMed Central 2021-08-04 /pmc/articles/PMC8336401/ /pubmed/34344479 http://dx.doi.org/10.1186/s41927-021-00196-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Rinkin, Charline Fosse, Pacôme Malaise, Olivier Chapelier, Nathalie Horrion, Jil Seidel, Laurence Albert, Adelin Hustinx, Roland Malaise, Michel G. Dissociation between 2-[(18)F]fluoro-2-deoxy-D-glucose positron emission computed tomography, ultrasound and clinical assessments in patients with non-severe rheumatoid arthritis, including remission |
title | Dissociation between 2-[(18)F]fluoro-2-deoxy-D-glucose positron emission computed tomography, ultrasound and clinical assessments in patients with non-severe rheumatoid arthritis, including remission |
title_full | Dissociation between 2-[(18)F]fluoro-2-deoxy-D-glucose positron emission computed tomography, ultrasound and clinical assessments in patients with non-severe rheumatoid arthritis, including remission |
title_fullStr | Dissociation between 2-[(18)F]fluoro-2-deoxy-D-glucose positron emission computed tomography, ultrasound and clinical assessments in patients with non-severe rheumatoid arthritis, including remission |
title_full_unstemmed | Dissociation between 2-[(18)F]fluoro-2-deoxy-D-glucose positron emission computed tomography, ultrasound and clinical assessments in patients with non-severe rheumatoid arthritis, including remission |
title_short | Dissociation between 2-[(18)F]fluoro-2-deoxy-D-glucose positron emission computed tomography, ultrasound and clinical assessments in patients with non-severe rheumatoid arthritis, including remission |
title_sort | dissociation between 2-[(18)f]fluoro-2-deoxy-d-glucose positron emission computed tomography, ultrasound and clinical assessments in patients with non-severe rheumatoid arthritis, including remission |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8336401/ https://www.ncbi.nlm.nih.gov/pubmed/34344479 http://dx.doi.org/10.1186/s41927-021-00196-1 |
work_keys_str_mv | AT rinkincharline dissociationbetween218ffluoro2deoxydglucosepositronemissioncomputedtomographyultrasoundandclinicalassessmentsinpatientswithnonsevererheumatoidarthritisincludingremission AT fossepacome dissociationbetween218ffluoro2deoxydglucosepositronemissioncomputedtomographyultrasoundandclinicalassessmentsinpatientswithnonsevererheumatoidarthritisincludingremission AT malaiseolivier dissociationbetween218ffluoro2deoxydglucosepositronemissioncomputedtomographyultrasoundandclinicalassessmentsinpatientswithnonsevererheumatoidarthritisincludingremission AT chapeliernathalie dissociationbetween218ffluoro2deoxydglucosepositronemissioncomputedtomographyultrasoundandclinicalassessmentsinpatientswithnonsevererheumatoidarthritisincludingremission AT horrionjil dissociationbetween218ffluoro2deoxydglucosepositronemissioncomputedtomographyultrasoundandclinicalassessmentsinpatientswithnonsevererheumatoidarthritisincludingremission AT seidellaurence dissociationbetween218ffluoro2deoxydglucosepositronemissioncomputedtomographyultrasoundandclinicalassessmentsinpatientswithnonsevererheumatoidarthritisincludingremission AT albertadelin dissociationbetween218ffluoro2deoxydglucosepositronemissioncomputedtomographyultrasoundandclinicalassessmentsinpatientswithnonsevererheumatoidarthritisincludingremission AT hustinxroland dissociationbetween218ffluoro2deoxydglucosepositronemissioncomputedtomographyultrasoundandclinicalassessmentsinpatientswithnonsevererheumatoidarthritisincludingremission AT malaisemichelg dissociationbetween218ffluoro2deoxydglucosepositronemissioncomputedtomographyultrasoundandclinicalassessmentsinpatientswithnonsevererheumatoidarthritisincludingremission |